<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006312.pub2" GROUP_ID="ANAESTH" ID="284004060110163708" MERGED_FROM="" MODIFIED="2016-01-29 10:45:11 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="118" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2016-01-29 10:45:11 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE>Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock</TITLE>
<CONTACT MODIFIED="2016-01-29 10:45:11 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="B59B51B682E26AA200F0756D754532E1" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Aziz</FIRST_NAME><LAST_NAME>Sheikh</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Primary Care Research &amp; Development</POSITION><EMAIL_1>Aziz.Sheikh@ed.ac.uk</EMAIL_1><EMAIL_2>asheikh2@partners.org</EMAIL_2><ADDRESS><DEPARTMENT>Allergy &amp; Respiratory Research Group and Asthma UK Centre for Applied Research</DEPARTMENT><ORGANISATION>Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh</ORGANISATION><ADDRESS_1>Teviot Place</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH8  9AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)131 650 8102</PHONE_1><FAX_1>+44 131 650 9119</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-01-29 10:45:11 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="B59B51B682E26AA200F0756D754532E1" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Aziz</FIRST_NAME><LAST_NAME>Sheikh</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Primary Care Research &amp; Development</POSITION><EMAIL_1>Aziz.Sheikh@ed.ac.uk</EMAIL_1><EMAIL_2>asheikh2@partners.org</EMAIL_2><ADDRESS><DEPARTMENT>Allergy &amp; Respiratory Research Group and Asthma UK Centre for Applied Research</DEPARTMENT><ORGANISATION>Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh</ORGANISATION><ADDRESS_1>Teviot Place</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH8  9AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)131 650 8102</PHONE_1><FAX_1>+44 131 650 9119</FAX_1></ADDRESS></PERSON><PERSON ID="10DBE40282E26AA200CFA52E396C9AED" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yasser</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Shehata</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>yasser.shehata@ed.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Community Health Sciences: GP section</DEPARTMENT><ORGANISATION>The University of Edinburgh</ORGANISATION><ADDRESS_1>20 West Richmond Street</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH8 9DX</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 0131 6506460</PHONE_1><FAX_1>+44 0131 6509119</FAX_1></ADDRESS></PERSON><PERSON ID="292ED72A82E26AA2004A583D608AED30" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Simon</FIRST_NAME><MIDDLE_INITIALS>GA</MIDDLE_INITIALS><LAST_NAME>Brown</LAST_NAME><SUFFIX>MBBS, PhD, FACEM</SUFFIX><EMAIL_1>simon.brown@uwa.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>The University of Western Australia at Fremantle Hospital</ORGANISATION><ADDRESS_1>Alma Street</ADDRESS_1><CITY>Fremantle</CITY><ZIP>6160</ZIP><REGION>Western Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>08 9431 3750</PHONE_1></ADDRESS></PERSON><PERSON ID="E6618A9882E26AA2001B9B03BA8AC0E1" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>F Estelle</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Simons</LAST_NAME><SUFFIX>MD, FRCPC</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>lmcniven@hsc.mb.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics &amp; Child Health; Department of Immunology</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Manitoba</ORGANISATION><CITY>Winnipeg</CITY><REGION>MB</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-06-18 10:43:12 +0100" MODIFIED_BY="Jane Cracknell">
<UP_TO_DATE>
<DATE DAY="30" MONTH="11" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="11" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="11" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2016-01-29 10:42:55 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-01-29 10:42:55 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="29" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>New contact details for lead author</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2014-06-18 10:42:07 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="18" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>This Cochrane review has been marked as stable no longer being updated as there are no randomized controlled trials (RCTs) and for ethical reasons there are unlikely to be any RCTs in the future. If the situation changes then the authors will update the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-06-18 10:41:17 +0100" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-18 10:41:17 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="23" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-23 13:11:24 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="18" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 14:46:35 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="15" MONTH="12" YEAR="2010"/>
<DESCRIPTION>
<P>New declaration of interest statement. Previously all authors stated: 'none known'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-15 13:09:36 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="30" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>In the previous version of our review, we searched the databases until March 2007. In this updated version we reran the database searches until November 2010.</P>
<P>We did not find any new studies which fitted our inclusion criteria.</P>
<P>We updated the methods section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-22 17:40:35 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="17" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Aziz Sheikh's affiliation updated; typos corrected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-17 16:17:27 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="11" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Edinburgh</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<SUMMARY MODIFIED="2008-08-04 13:48:07 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Adrenaline for the emergency treatment of anaphylaxis</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-04 13:48:07 +0100" MODIFIED_BY="[Empty name]">
<P>Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. It is commonly triggered by a food, insect sting, medication, or natural rubber latex. The reaction occurs without warning and can be a frightening experience for those at risk and for their families and friends. Adrenaline (epinephrine) is widely advocated as the main treatment in those individuals experiencing anaphylaxis. There is no other medication with a similar effect on the many body systems that are potentially involved in anaphylaxis. The evidence base in support of the use of adrenaline is unclear. We therefore conducted a systematic review of the literature searching key databases for high quality published and unpublished material on the use of adrenaline for emergency treatment; in addition, we contacted experts in this area and the relevant pharmaceutical companies. Our searches retrieved no randomized controlled trials on this subject. We concluded that the use of adrenaline in anaphylaxis is based on tradition and on evidence from fatality series in which most individuals dying from anaphylaxis had not received prompt adrenaline treatment. Adrenaline appears to be life saving when injected promptly, however, there is no evidence from randomized controlled trials for or against the use of adrenaline in the emergency treatment of anaphylaxis. Given the infrequency of anaphylaxis, its unpredictability and the speed of onset of reactions, conducting such trials is fraught with ethical and methodological difficulties.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<ABS_BACKGROUND MODIFIED="2008-05-26 11:29:09 +0100" MODIFIED_BY="[Empty name]">
<P>Anaphylaxis is a serious hypersensitivity reaction that is rapid in onset and may cause death. Adrenaline is recommended as the initial treatment of choice for anaphylaxis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the benefits and harms of adrenaline (epinephrine) in the treatment of anaphylaxis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<P>In the previous version of our review, we searched the databases until March 2007. In this version we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2010, Issue 11), MEDLINE (1966 to November 2010), EMBASE (1966 to November 2010), CINAHL (1982 to November 2010), BIOSIS (to November 2010), ISI Web of Knowledge (to November 2010 and LILACS (1982 to November 2010). We also searched websites listing ongoing trials and contacted pharmaceutical companies and international experts in anaphylaxis in an attempt to locate unpublished material.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<P>We included randomized and quasi-randomized controlled trials comparing adrenaline with no intervention, placebo or other adrenergic agonists were eligible for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed articles for inclusion.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-04 15:37:42 +0100" MODIFIED_BY="Jane Cracknell">
<P>We found no studies that satisfied the inclusion criteria.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-06-27 06:42:53 +0100" MODIFIED_BY="[Empty name]">
<P>Based on this review, we are unable to make any new recommendations on the use of adrenaline for the treatment of anaphylaxis. Although there is a need for randomized, double-blind, placebo-controlled clinical trials of high methodological quality in order to define the true extent of benefits from the administration of adrenaline in anaphylaxis, such trials are unlikely to be performed in individuals with anaphylaxis. Indeed, they might be unethical because prompt treatment with adrenaline is deemed to be critically important for survival in anaphylaxis. Also, such studies would be difficult to conduct because anaphylactic episodes usually occur without warning, often in a non-medical setting, and differ in severity both among individuals and from one episode to another in the same individual. Consequently, obtaining baseline measurements and frequent timed measurements might be difficult, or impossible, to obtain. In the absence of appropriate trials, we recommend, albeit on the basis of less than optimal evidence, that adrenaline administration by intramuscular (i.m.) injection should still be regarded as first-line treatment for the management of anaphylaxis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<BACKGROUND MODIFIED="2008-08-04 15:45:51 +0100" MODIFIED_BY="Jane Cracknell">
<P>Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death (<LINK REF="REF-Sampson-2006" TYPE="REFERENCE">Sampson 2006</LINK>). Trigger factors include foods, insect venoms, medications, anaesthetics, natural rubber latex, and exercise (<LINK REF="REF-Brown-2001" TYPE="REFERENCE">Brown 2001</LINK>; <LINK REF="REF-Brown-2004a" TYPE="REFERENCE">Brown 2004a</LINK>; <LINK REF="REF-Kemp-2002" TYPE="REFERENCE">Kemp 2002</LINK>; <LINK REF="REF-Lieberman-2003" TYPE="REFERENCE">Lieberman 2003</LINK>; <LINK REF="REF-Sampson-2005" TYPE="REFERENCE">Sampson 2005</LINK>; <LINK REF="REF-Simons-2002a" TYPE="REFERENCE">Simons 2002a</LINK>; <LINK REF="REF-Simons-2007a" TYPE="REFERENCE">Simons 2007a</LINK>; <LINK REF="REF-Simons-2007b" TYPE="REFERENCE">Simons 2007b</LINK>). Most anaphylactic episodes involve an immediate hypersensitivity reaction following allergen interaction with cell-bound immunoglobulin E (IgE). Less commonly other immunologic mechanisms, for example autoimmune mechanisms, are involved; or no immune mechanism is involved, for example when anaphylaxis is triggered by exposure to cold air or water. Some individuals have idiopathic anaphylaxis with no obvious trigger. Regardless of the inciting mechanism, the final common pathway involves release of histamine and other mediators from mast cells and basophils. Distinction between anaphylactic reactions and an anaphylactoid reaction is no longer recommended as the clinical picture and emergency treatment of anaphylaxis are similar regardless of the pathophysiologic mechanism (<LINK REF="REF-Johansson-2001" TYPE="REFERENCE">Johansson 2001</LINK>; <LINK REF="REF-Johansson-2004" TYPE="REFERENCE">Johansson 2004</LINK>; <LINK REF="REF-Sampson-2006" TYPE="REFERENCE">Sampson 2006</LINK>; <LINK REF="REF-Simons-2007a" TYPE="REFERENCE">Simons 2007a</LINK>).</P>
<P>Anaphylaxis is not a reportable disease and the true incidence is unknown (<LINK REF="REF-Bohlke-2004" TYPE="REFERENCE">Bohlke 2004</LINK>; <LINK REF="REF-Hebling-2004" TYPE="REFERENCE">Hebling 2004</LINK>; <LINK REF="REF-Klein-1995" TYPE="REFERENCE">Klein 1995</LINK>; <LINK REF="REF-Lieberman-2006" TYPE="REFERENCE">Lieberman 2006</LINK>; <LINK REF="REF-Neugut-2001" TYPE="REFERENCE">Neugut 2001</LINK>; <LINK REF="REF-Peng-2004" TYPE="REFERENCE">Peng 2004</LINK>; <LINK REF="REF-Sheikh-2001" TYPE="REFERENCE">Sheikh 2001</LINK>). An estimate of the incidence in the general population is influenced by definitions, which differ from one investigator to another, as well as by coding issues and misclassification errors (<LINK REF="REF-Clark-2006" TYPE="REFERENCE">Clark 2006</LINK>). A population-based study using data collected in the mid-1980s calculated an annual incidence of 30 per 100,000 person years, which raised concern that anaphylaxis was frequently not recognized (<LINK REF="REF-Yocum-1999" TYPE="REFERENCE">Yocum 1999</LINK>). Other studies suggest the true incidence may be up to 590 per 100,000 person years. Anaphylaxis from the four most common triggers (foods, insect stings, medications, and natural rubber latex) may affect more than 1% of the general population (<LINK REF="REF-Neugut-2001" TYPE="REFERENCE">Neugut 2001</LINK>) with considerable variations in age (<LINK REF="REF-Simons-2002a" TYPE="REFERENCE">Simons 2002a</LINK>) and in age-specific aetiology (<LINK REF="REF-Alves-2001" TYPE="REFERENCE">Alves 2001</LINK>).</P>
<P>Skin symptoms and signs, including generalised urticaria, flushing, itching, and angioedema (swelling of the subcutaneous tissues), are the most common manifestations of anaphylaxis (in 90% of those affected) followed by respiratory (70%) and gastrointestinal (40%) symptoms; hypotension occurs in 10% to 30% (<LINK REF="REF-Brown-2001" TYPE="REFERENCE">Brown 2001</LINK>; <LINK REF="REF-Brown-2004b" TYPE="REFERENCE">Brown 2004b</LINK>; <LINK REF="REF-Kemp-2002" TYPE="REFERENCE">Kemp 2002</LINK>; <LINK REF="REF-Lieberman-2003" TYPE="REFERENCE">Lieberman 2003</LINK>; <LINK REF="REF-Simons-2002b" TYPE="REFERENCE">Simons 2002b</LINK>). Symptoms often occur within five to 30 minutes of exposure to the trigger factor, although occasionally they do not develop for several hours. Anaphylaxis may be fatal within minutes, usually through cardiovascular or respiratory compromise, or both (<LINK REF="REF-Bock-2007" TYPE="REFERENCE">Bock 2007</LINK>; <LINK REF="REF-Greenberger-2007" TYPE="REFERENCE">Greenberger 2007</LINK>; <LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>; <LINK REF="REF-Pumphrey-2007" TYPE="REFERENCE">Pumphrey 2007</LINK>). Upper and lower respiratory tract obstruction is commonly reported in fatal cases (<LINK REF="REF-Bock-2007" TYPE="REFERENCE">Bock 2007</LINK>; <LINK REF="REF-Greenberger-2007" TYPE="REFERENCE">Greenberger 2007</LINK>; <LINK REF="REF-Pumphrey-2007" TYPE="REFERENCE">Pumphrey 2007</LINK>). True mortality rates are unknown in anaphylaxis because of under-recognition and under-diagnosis of the disease (<LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>).</P>
<P>The diagnosis of anaphylaxis is based largely on history and physical findings. Laboratory tests have proven to be disappointing in clinical practice. Plasma histamine may be elevated, but it is only reliable when measured within one hour of onset and the levels are not stable during routine handling, so it is seldom used (<LINK REF="REF-Lin-2000" TYPE="REFERENCE">Lin 2000</LINK>). Serum or plasma tryptase levels greater than 15 ng/mL within 12 hours (preferably within three hours) of the onset of an episode is more widely used as a confirmatory test, but this test is usually negative in food-induced anaphylaxis. Serial total serum or plasma tryptase measurements may be more helpful than single measurements (<LINK REF="REF-Brown-2004a" TYPE="REFERENCE">Brown 2004a</LINK>). Positive skin tests to allergens and elevated allergen-specific IgE levels in serum are not diagnostic of anaphylaxis. Rather, such tests confirm sensitization and provide clinically relevant information that directs risk reduction and the prevention of future episodes by avoidance of specific allergen or allergens; or long-term immunomodulation where relevant, for example with venom immunotherapy for insect sting anaphylaxis (<LINK REF="REF-Simons-2007a" TYPE="REFERENCE">Simons 2007a</LINK>). </P>
<P>Adrenaline (epinephrine) is widely advocated as the initial treatment of choice for anaphylaxis (<LINK REF="REF-Alrasbi-2007" TYPE="REFERENCE">Alrasbi 2007</LINK>; <LINK REF="REF-McLean_x002d_Tooke-2003" TYPE="REFERENCE">McLean-Tooke 2003</LINK>; <LINK REF="REF-Simons-2004" TYPE="REFERENCE">Simons 2004</LINK>). This initial emergency management is supervised by a physician or other healthcare professional when anaphylaxis occurs in a healthcare setting. In this setting intramuscular (i.m.) or intravenous (i.v.) infusion, or both, routes for adrenaline are preferred (<LINK REF="REF-Brown-2006" TYPE="REFERENCE">Brown 2006</LINK>). When anaphylaxis occurs in the community, in a non-medical setting, the standard of first-aid treatment is the administration of self-injectable adrenaline into the anterolateral thigh using an EpiPen, Anapen, AnaHelp, Fastject, Twinject, or other adrenaline formulation (<LINK REF="REF-Sicherer-2005" TYPE="REFERENCE">Sicherer 2005</LINK>; <LINK REF="REF-Simons-2004" TYPE="REFERENCE">Simons 2004</LINK>).</P>
<P>Adrenaline is an alpha- and beta-adrenergic agonist (that is it acts on two different important classes of receptors in the body) with bidirectional cyclic adenosine monophosphate-mediated pharmacologic effects on target organs and a narrow therapeutic index (<LINK REF="REF-Simons-2006" TYPE="REFERENCE">Simons 2006</LINK>). It results in vasoconstriction, increased peripheral vascular resistance, decreased mucosal oedema, inotropic and chronotropic effects (increased force and rate of cardiac action), bronchodilation, and decreased mediator release from mast cells and basophils. The plasma and tissue concentrations of adrenaline needed for recovery from anaphylaxis have not yet been defined in humans (<LINK REF="REF-Simons-2004" TYPE="REFERENCE">Simons 2004</LINK>). There have been no prospective human studies performed during the management of anaphylaxis to evaluate the bioavailability and optimal dose of adrenaline given intramuscularly or to assess the incidence of adverse effects (<LINK REF="REF-Simons-2008" TYPE="REFERENCE">Simons 2008</LINK>). Case reports and large mortality reviews indicate that side effects involving the myocardium can be serious, usually in the setting of inappropriate dosing (an overdose, an inadequately diluted intravenous dose, or an overly rapid rate of infusion) by medical staff (<LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>). However, there is now increased awareness that the heart itself may be a target organ in anaphylaxis and that electrocardiographic changes suggesting ischaemia, myocardial failure, and dysrhythmias can occur even if adrenaline has not been given (<LINK REF="REF-Brown-2005" TYPE="REFERENCE">Brown 2005</LINK>; <LINK REF="REF-Kounis-2006" TYPE="REFERENCE">Kounis 2006</LINK>; <LINK REF="REF-Marone-2004" TYPE="REFERENCE">Marone 2004</LINK>).</P>
<P>Only the intravenous route was used in the two studies in humans that indicate a beneficial treatment effect for reactions characterised by cardiovascular collapse (<LINK REF="REF-Brown-2004b" TYPE="REFERENCE">Brown 2004b</LINK>; <LINK REF="REF-Fisher-1978" TYPE="REFERENCE">Fisher 1978</LINK>). In a canine model of fully-developed anaphylactic shock (defined as hypotension with the blood pressure contained at 50% of baseline blood pressure), adrenaline 0.01 mg/kg injected by the intramuscular route was ineffective; an intravenous bolus of 0.01 mg/kg resulted in transient improvement; and intravenous infusion at 0.19 to 0.45 &#956;g/kg/min was the only method to produce a sustained improvement (<LINK REF="REF-Bautista-2002" TYPE="REFERENCE">Bautista 2002</LINK>; <LINK REF="REF-Mink-2004" TYPE="REFERENCE">Mink 2004</LINK>). The therapeutic effect in this model was from positive inotropy, with no increases in either systemic vascular resistance or pulmonary arterial wedge pressure. Thus, if a severe reaction develops and adrenaline is administered at the generally recommended initial doses for anaphylaxis, which are lower than the doses recommended for resuscitation, it might not adequately counteract the effects of vasodilation and distributive-hypovolaemic shock on its own, even when given as an intravenous infusion (<LINK REF="REF-Brown-2005" TYPE="REFERENCE">Brown 2005</LINK>).</P>
<P>In summary, the use of adrenaline in anaphylaxis appears to be based largely on extrapolation from first principles, expert opinion, and tradition.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the benefits and harms of adrenaline in the treatment of anaphylaxis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<SELECTION_CRITERIA MODIFIED="2008-06-20 10:31:01 +0100" MODIFIED_BY="Jane Cracknell">
<CRIT_STUDIES MODIFIED="2008-06-27 07:35:50 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to include randomized controlled trials comparing adrenaline with no intervention, placebo, or other adrenergic agonists. We also planned to include randomized controlled trials comparing different approaches to the administration of adrenaline and quasi-randomized controlled trials, that is trials where an attempt to approximate randomization was made (for example by alternate allocation). Controlled trials with little attempt to minimize bias during allocation were, however, not eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-06-27 07:36:15 +0100" MODIFIED_BY="[Empty name]">
<P>We were interested in all patients (infants, children and adults; community or hospital based) experiencing anaphylaxis caused by food, insect venom, medication, vaccination, latex, or any other trigger.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-06-27 07:43:20 +0100" MODIFIED_BY="[Empty name]">
<P>We were interested in studies involving any systemic (intravenous infusion or bolus injection, intramuscular, subcutaneous, or inhaled from a metered-dose inhaler or a nebulizer) administration of adrenaline by the individual, a lay caregiver (of a child), or a medical professional. Adrenaline could have been administered anywhere in the community, including in a physician's office or an ambulance; or anywhere in the hospital, including emergency departments, hospital clinics, dialysis units, wards, operating rooms, and delivery rooms. It may also have been administered after another medication. The comparative treatments of interest were no intervention, placebo, other adrenergic agonists; and different treatment approaches to the administration of adrenaline.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-06-27 07:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>Our outcome measures of interest were the following.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-06-04 10:42:31 +0100" MODIFIED_BY="Karen Hovhannisyan">
<P>Death</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-06-27 07:44:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Resolution of upper airway obstruction</LI>
<LI>Resolution of lower airway obstruction (symptomatic bronchospasm)</LI>
<LI>Improvement in arterial blood pressure (greater than 50 mm Hg systolic)</LI>
<LI>Resolution of urticaria</LI>
<LI>Requirement for second dose of adrenaline</LI>
<LI>Admission to hospital</LI>
<LI>Length of emergency department stay</LI>
<LI>Length of hospital stay</LI>
<LI>Re-presentation for therapy within 24 hours</LI>
<LI>Adverse events due to therapy, in either treatment arm</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-29 12:03:19 +0000" MODIFIED_BY="Jane Cracknell">
<ELECTRONIC_SEARCHES MODIFIED="2010-11-29 12:03:19 +0000" MODIFIED_BY="Jane Cracknell">
<P>In the previous version of our review, we searched all the databases until March 2007.</P>
<P>In this updated version we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2010<I>,</I> Issue 11) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>); MEDLINE (1966 to November 2010, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>); EMBASE (1966 to November 2010, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>); CINAHL (1982 to November 2010, <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>); BIOSIS (1969 to November 2010, <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>); ISI Web of Science (1956 to November 2010, <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> ); and LILACS (1982 to November 2010), <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
<P>We searched MEDLINE using Ovid with the Cochrane randomized controlled trial filter (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) and the following key words: anaphyl* and adrenaline. We adopted our search terms for other databases. We did not apply any language restriction.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-02 11:18:15 +0100" MODIFIED_BY="Jane Cracknell">
<P>In an attempt to uncover any additional relevant published data, grey literature, unpublished data, and research in progress, we:</P>
<UL>
<LI>contacted international experts in anaphylaxis (see <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>);</LI>
<LI>contacted relevant pharmaceutical companies (see <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>);</LI>
<LI>searched the UK's National Research Register: <A HREF="https://portal.nihr.ac.uk/pages/nrrarchive.aspx">https://portal.nihr.ac.uk/Pages/NRRArchive.aspx</A>
</LI>
<LI>searched websites listing ongoing trials: <A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>, <A HREF="http://www.controlledtrials.com/">http://www.controlledtrials.com/</A> and <A HREF="http://www.actr.org.au/">http://www.actr.org.au/</A>.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two authors (YS and AS) independently reviewed titles and abstracts identified from literature searches for relevant trials and selected possibly relevant studies. We reviewed these studies using the full text and assessed them using the inclusion criteria detailed above.</P>
<P>We had agreed that we would resolve any disagreements by discussion between both of the authors; in the case of consensus not being reached, a third author (ES) would become involved and, if necessary, arbitrate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>We stipulated that two authors (YS and AS) would independently extract data using a suitably adapted version of the data extraction form developed by the Cochrane Anaesthesia Review Group. We stated that we would resolve any disagreements by discussion between both of the authors; in the case of consensus not being reached, a third author (ES) was to be involved and, if necessary, arbitrate. This did not prove necessary.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality of included studies</HEADING>
<P>In our previous version we planned to grade each parameter of trial quality as: A - low risk of bias; B - moderate risk of bias; C - high risk of bias. We planned to make an overall assessment for each randomized controlled trial, using the same rating scale.</P>
<P>In this updated version of the review we planned to assess the quality of included RCTs following the Cochrane approach using the methods detailed in Chapter Eight of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>We planned to construct risk of bias tables to support judgements of quality using the Cochrane Risk of Bias tool (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>):</P>
<UL>
<LI>Was the allocation sequence adequately generated?</LI>
</UL>
<UL>
<LI>Was allocation adequately concealed?</LI>
</UL>
<UL>
<LI>Was knowledge of the allocated interventions adequately prevented during the study?</LI>
</UL>
<UL>
<LI>Were incomplete outcome data adequately addressed?</LI>
</UL>
<UL>
<LI>Are reports of the study free of suggestion of selective outcome reporting?</LI>
</UL>
<UL>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
<P>W e planned to record the judgement as 'yes' indicating that the study met that quality parameter, 'no' it did not<BR/>or 'unclear' indicating that there was insufficient evidence to make a judgement either way.<BR/>
<BR/>We planned to display the results by creating a 'Risk of bias' graph and a 'Risk of bias' summary figure using <LINK REF="REF-RevMan-5.0" TYPE="REFERENCE">RevMan 5.0</LINK> software</P>
<P>We also planned to subject quasi-randomized studies to methodological assessment, in which case two authors (YS and AS) would independently assess study quality; review authors would not be masked to study details. We planned to assess the agreement of review authors on methodological quality assessment and to resolve disagreements by discussion and, if necessary, with the involvement of a third author (ES).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We proposed to use Review Manager (<LINK REF="REF-RevMan-5.0" TYPE="REFERENCE">RevMan 5.0</LINK>) for data analysis and quantitative data synthesis. For dichotomous data, we planned to calculate individual and pooled statistics as relative risks (RR) with 95% confidence intervals (95% CI). For continuous data, we planned to calculate individual and pooled statistics as mean differences (MD) or standardized means differences, or both, with 95% CI. We planned to consider the appropriateness of meta-analysis in the presence of significant clinical or statistical heterogeneity. We assumed significant heterogeneity if the I<SUP>2</SUP> statistic was greater than 40% (that is more than 40% of the variability in outcome between trials could not be explained by sampling variation) (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). We planned to undertake meta-analysis using a fixed-effect model in the absence of statistical heterogeneity and a random-effects model if such heterogeneity was likely. We planned to explore any statistical or clinical heterogeneity by using sensitivity or subgroup analysis (see below). We planned to undertake quantitative analyses of outcomes on an intention-to-treat basis, wherever possible. We planned to assess any evidence of publication bias graphically using funnel plots and statistically using Begg and Egger tests (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>; <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>In the event of uncovering significant heterogeneity, we planned to investigate the heterogeneity by undertaking subgroup analyses. Our subgroups of interest were:</P>
<UL>
<LI>presence or absence of shock;</LI>
<LI>mild or more severe anaphylaxis (<LINK REF="REF-Brown-2004b" TYPE="REFERENCE">Brown 2004b</LINK>);</LI>
<LI>mode of administration of treatment (i.m. versus i.v.; administered by patient versus healthcare professional);</LI>
<LI>time from onset of anaphylaxis to receiving treatment;</LI>
<LI>age (infants, children, and adults);</LI>
<LI>trigger agents (iatrogenic versus community, antibiotic versus other drugs, and muscle relaxants versus other agents).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We planned to undertake sensitivity analysis for the allocation of missing data by best and worst case analysis and also to undertake sensitivity analysis on the basis of only including randomized studies. This would allow an assessment of the impact on the review conclusions of excluding quasi-randomized studies, judged to be at increased risk of bias.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY_DESCRIPTION MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<P>In the previous version of our review, we searched the databases until March 2007 and yielded 382 citations. In this updated version we searched from March 2007 up to November 2010 and found an additional 1036 citations. In total our combined searches found 1418 citations (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>After scrutiny of the abstracts of these studies, no studies fulfilled the inclusion criteria. We contacted context editors and pharmaceutical companies but this failed to contribute any relevant published or unpublished studies. The search of the UK National Research Register, Current Controlled Trials, and Clinical Trials using anaphylaxis as a keyword identified no useful articles.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>There were no eligible studies.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>There were no eligible studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-04 15:42:23 +0100" MODIFIED_BY="Jane Cracknell">
<P>This review failed to uncover any evidence from prospective, randomized or quasi-randomized trials on the effectiveness of adrenaline for the emergency management of anaphylaxis. Given the relative infrequency of the condition, the speed of onset, the often unexpected occurrence, and the established place of adrenaline in treatment guidelines internationally (<LINK REF="REF-Alrasbi-2007" TYPE="REFERENCE">Alrasbi 2007</LINK>) this lack of evidence for a treatment that was introduced well before the evidence-based medicine era is perhaps unsurprising (<LINK REF="REF-Simons-2007b" TYPE="REFERENCE">Simons 2007b</LINK>).</P>
<P>The optimal route of administration and the optimal dose of adrenaline have not yet been defined. In children, it has been shown that subcutaneous administration of adrenaline was associated with a striking difference in the time of maximum plasma adrenaline concentrations compared with the intramuscular route (<LINK REF="REF-Simons-1998" TYPE="REFERENCE">Simons 1998</LINK>). Other studies showed that the average maximum plasma concentration was also significantly higher for the intramuscular route than for the subcutaneous route of administration (<LINK REF="REF-Simons-2001" TYPE="REFERENCE">Simons 2001</LINK>). Moreover, guidelines regarding the treatment of anaphylaxis have recommended against use of the subcutaneous route (<LINK REF="REF-Chamberlain-1999" TYPE="REFERENCE">Chamberlain 1999</LINK>).</P>
<P>Some disagreement exists about the recommended dose of adrenaline. Almost all of the literature agrees on 0.01 mg/kg in infants and children. Although North American, Australasian, and current UK guidelines suggest a maximum initial dose of 0.3 to 0.5 mg of adrenaline in adults, some older European literature suggests 0.5 to 1.0 mg as a maximum initial intramuscular dose in adults (<LINK REF="REF-Alrasbi-2007" TYPE="REFERENCE">Alrasbi 2007</LINK>; <LINK REF="REF-Soar-2008" TYPE="REFERENCE">Soar 2008</LINK>).</P>
<P>Delayed injection of adrenaline in anaphylaxis is reported to be associated with mortality (<LINK REF="REF-Bock-2001" TYPE="REFERENCE">Bock 2001</LINK>; <LINK REF="REF-Bock-2007" TYPE="REFERENCE">Bock 2007</LINK>; <LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>; <LINK REF="REF-Pumphrey-2007" TYPE="REFERENCE">Pumphrey 2007</LINK>; <LINK REF="REF-Greenberger-2007" TYPE="REFERENCE">Greenberger 2007</LINK>). Given that current evidence supports the relative safety of intramuscular adrenaline, and early administration is believed to be associated with an improved survival, any patient with a serious allergic reaction that is rapid in onset should be a candidate for adrenaline by auto-injector.</P>
<P>Adrenaline has been associated with the induction of fatal cardiac arrhythmias and myocardial infarction. Major adverse events usually occur when adrenaline has been given in an excessive dose, an inadequately diluted intravenous dose, or an overly rapid rate of infusion (<LINK REF="REF-Brown-1998" TYPE="REFERENCE">Brown 1998</LINK>; <LINK REF="REF-Fischer-1995" TYPE="REFERENCE">Fischer 1995</LINK>; <LINK REF="REF-Montanaro-2002" TYPE="REFERENCE">Montanaro 2002</LINK>; <LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>). Historically, those individuals thought to be particularly at risk of adverse effects of adrenaline include elderly patients and patients with hypertension, arteriopathies, or known ischaemic heart disease ( <LINK REF="REF-Bock-2001" TYPE="REFERENCE">Bock 2001</LINK>; <LINK REF="REF-Bock-2007" TYPE="REFERENCE">Bock 2007</LINK>; <LINK REF="REF-Greenberger-2007" TYPE="REFERENCE">Greenberger 2007</LINK>; <LINK REF="REF-Muller-2007" TYPE="REFERENCE">Muller 2007</LINK>; <LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>; <LINK REF="REF-Pumphrey-2007" TYPE="REFERENCE">Pumphrey 2007</LINK>; <LINK REF="REF-Sampson-1992" TYPE="REFERENCE">Sampson 1992</LINK>); however, these patients may also be at increased risk from the anaphylactic episode itself. It is difficult, particularly in retrospect, to dissect potential adverse effects of adrenaline from the known effects of anaphylaxis (<LINK REF="REF-Brown-1998" TYPE="REFERENCE">Brown 1998</LINK>; <LINK REF="REF-Marone-2004" TYPE="REFERENCE">Marone 2004</LINK>; <LINK REF="REF-Pumphrey-2000" TYPE="REFERENCE">Pumphrey 2000</LINK>). Because of potential harm from the use of intravenous adrenaline in inexperienced hands, guidelines generally recommend that the intravenous route is reserved for cases that do not respond to initial treatment with intramuscular adrenaline and where cardiovascular collapse and cardiac arrest is considered imminent. A controlled infusion is safer than bolus administration (<LINK REF="REF-Soar-2008" TYPE="REFERENCE">Soar 2008</LINK>). It should be given in a resuscitation area that has electrocardiography and physiological monitoring by medical and nursing staff who are trained in its use (<LINK REF="REF-Johnston-2003" TYPE="REFERENCE">Johnston 2003</LINK>).</P>
<P>In the past, adrenaline has been available worldwide in metered-dose inhaler formulations. These are no longer available in many countries due to their chlorofluorocarbon (CFC) propellant content and the phase out of CFC-containing medications. Inhalation of a few puffs of adrenaline from a pressurized metered-dose inhaler is not adequate for treatment of most of the symptoms in anaphylaxis. In order to achieve systemic effects, adults need to inhale 20 to 30 puffs, and children need to inhale 10 to 20 puffs (<LINK REF="REF-Heilborn-1986" TYPE="REFERENCE">Heilborn 1986</LINK>; <LINK REF="REF-Simons-2000" TYPE="REFERENCE">Simons 2000</LINK>). For an overview of the context in which adrenaline should be used in anaphylaxis: provide supplemental oxygen; place patient in the supine position, if tolerated; start volume resuscitation; and prepare for intubation, the appropriate references should be consulted (<LINK REF="REF-Soar-2008" TYPE="REFERENCE">Soar 2008</LINK>).  </P>
<P>As there are no controlled trials there is no way to estimate the risk in relation to benefit. Based on the current evidence, we believe that the benefit of using appropriate doses of intramuscular adrenaline is likely to far exceed the risk. Anaesthetists, who see anaphylaxis relatively commonly, usually have sophisticated monitoring in place before, during, and after the event; they report a rapid and predictable response to adrenaline that is near universal. It should be stressed that adrenaline is not contraindicated in individuals with underlying ischaemic heart disease as the decrease in filling pressure due to anaphylaxis is likely to result in further coronary ischaemia (<LINK REF="REF-Montanaro-2002" TYPE="REFERENCE">Montanaro 2002</LINK>). Careful monitoring and avoidance of an adrenaline overdose is necessary in these patients, however.</P>
<P>There is a strong clinical impression that prompt injection of adrenaline is life saving in anaphylaxis. Given the uncertainties surrounding its use, however, a firmer evidence base needs to be developed, if possible. Conducting research in this area is challenging for several reasons, including:</P>
<UL>
<LI>·the established position of adrenaline treatment thereby making it difficult to argue for placebo-controlled trials;</LI>
<LI>the ethical issues involved in obtaining informed consent (or deferring consent) in emergency situations (<LINK REF="REF-Dec-Helsinki--1996" TYPE="REFERENCE">Dec Helsinki 1996</LINK>);</LI>
<LI>difficulty in conducting double-blind, placebo-controlled studies due to the transient pharmacologic effects (pallor, tachycardia, tremor) of adrenaline in standard doses that reverse airway obstruction and circulatory collapse;   </LI>
<LI>logistical issues: anaphylactic episodes usually occur without warning, often in a non-medical setting; differ in severity from one individual to another, and from one episode to another in the same individual;</LI>
<LI>difficulty in obtaining baseline measurements;</LI>
<LI>the lack of any information on the pharmacokinetics and pharmacodynamics of adrenaline when given to humans during anaphylaxis and a lack of any prospectively collected information on clinical outcomes, both of which are required to construct valid hypotheses and inform sample size calculations for a clinical trial.</LI>
</UL>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-20 10:17:15 +0100" MODIFIED_BY="Jane Cracknell">
<IMPLICATIONS_PRACTICE MODIFIED="2008-06-27 08:30:46 +0100" MODIFIED_BY="[Empty name]">
<P>We found no relevant evidence for adrenaline use in the treatment of anaphylaxis. We are, therefore, unable to make any new recommendations based on the findings of this review. Guidelines on the management of anaphylaxis need to be more explicit about the basis of their recommendations regarding the use of adrenaline.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-04 13:59:35 +0100" MODIFIED_BY="[Empty name]">
<P>Given the routine use of adrenaline in the management of anaphylaxis, there is a need for academic debate about the ethics and practicality of mounting randomized trials in order to define the true extent, if any, of benefits from the administration of adrenaline in anaphylaxis. Specifically, more information is required on the subset of patients more likely to benefit from this therapy and the most appropriate preparations, route, and dose of administration.</P>
<P>Although placebo-controlled trials of adrenaline in anaphylaxis would be unethical, it might be possible to conduct randomized controlled trials comparing two different doses of adrenaline, or two different routes of administration of adrenaline, in addition to other standard-of-care treatments (<LINK REF="REF-Simons-2008" TYPE="REFERENCE">Simons 2008</LINK>).</P>
<P>Any future trials would need to consider in particular:</P>
<UL>
<LI>appropriate sample size with power to detect expected difference;</LI>
<LI>careful definition and selection of target patients;</LI>
<LI>appropriate comparator therapy;</LI>
<LI>appropriate outcome measures;</LI>
<LI>careful elucidation of any adverse effects; and</LI>
<LI>the cost-effectiveness of the therapy.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<P>November 2010: We would like to thank the Anaesthesia Group&#8217;s Trials Search Co-ordinator (Karen Hovhannisyan) for rerunning all the searches for the updated version of the review.</P>
<P>We would like to thank Prof Anthony Brown and Prof Hugh Sampson for their help and advice during the preparation of this review. Our thanks to Anna Wierzoch and Jane Cracknell for their help during the course of conducting this review.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by an editor and three peer reviewers (who are external to the editorial team), one or more members of the Cochrane Consumer Network&#8217;s international panel of consumers and the Anaesthesia Group&#8217;s Trials Search Co-ordinator.</P>
<P>We would thank to thank Prof Mike Bennett, Dr Jose Mª Negro, Dr Ulrich Müller and Dr Phil Lieberman, Rosemary Humphreys and Janet Wale for their help and editorial advice during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-12-15 13:14:32 +0000" MODIFIED_BY="Jane Cracknell">
<P>Aziz Sheikh:has obtained funding from ALK-Abello to support conference attendance by members of our research group.</P>
<P> Yasser A Shehata, Simon GA Brown and F Estelle R Simons: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<P>Conceiving the review: Aziz Sheikh (AS) and F. Estelle R Simons (ES)<BR/>Co-ordinating the review: AS<BR/>Undertaking manual searches: Yasser A Shehata (YS)<BR/>Screening search results: YS and AS<BR/>Organizing retrieval of papers: YS<BR/>Screening retrieved papers against inclusion criteria: YS and AS<BR/>Appraising quality of papers: Not applicable<BR/>Abstracting data from papers: Not applicable<BR/>Writing to authors of papers for additional information: YS and AS<BR/>Providing additional data about papers: Not applicable<BR/>Obtaining and screening data on unpublished studies: Not applicable<BR/>Data management for the review: YS<BR/>Entering data into Review Manager (<LINK REF="REF-RevMan-5.0" TYPE="REFERENCE">RevMan 5.0</LINK>): YS<BR/>RevMan statistical data: Not applicable<BR/>Other statistical analysis not using RevMan: Not applicable<BR/>Double entry of data: (data entered by person one: data entered by person two:) Not applicable<BR/>Interpretation of data: Not applicable<BR/>Statistical analysis: Not applicable<BR/>Writing the review: AS, ES, Simon GA Brown (SB) and YS<BR/>Securing funding for the review: AS<BR/>Performing previous work that was the foundation of the present study: AS, ES and SB<BR/>Guarantor for the review (one author): AS<BR/>Person responsible for reading and checking review before submission: AS<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-30 12:37:34 +0000" MODIFIED_BY="Jane Cracknell">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-30 12:37:34 +0000" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-30 12:37:34 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Alrasbi-2007" MODIFIED="2008-06-20 10:45:40 +0100" MODIFIED_BY="Jane Cracknell" NAME="Alrasbi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Alrasbi M, Sheikh A</AU>
<TI>Comparison of international guidelines for the emergency medical management of anaphylaxis</TI>
<SO>Allergy</SO>
<YR>2007</YR>
<VL>62</VL>
<PG>838-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alves-2001" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Alves 2001" TYPE="JOURNAL_ARTICLE">
<AU>Alves B, Sheikh A</AU>
<TI>Age specific aetiology of anaphylaxis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>85</VL>
<PG>348</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bautista-2002" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bautista 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bautista E, Simons FER, Simons KJ, Becker AB, Duke K, Tillett M, et al</AU>
<TI>Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock</TI>
<SO>International Archives of Allergy and Applied Immunology</SO>
<YR>2002</YR>
<VL>128</VL>
<PG>151-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<PG>1088-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bock-2001" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bock 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bock SA, Munoz-Furlong A, Sampson HA</AU>
<TI>Fatalities due to anaphylactic reactions to foods</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bock-2007" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bock 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bock SA, Munoz-Furlong A, Sampson HA</AU>
<TI>Further fatalities caused by anaphylactic reactions to food, 2001-2006</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<PG>1016-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohlke-2004" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bohlke 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS, Vaccine Safety Datalink Team</AU>
<TI>Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<PG>536-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1998" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Brown 1998" TYPE="JOURNAL_ARTICLE">
<AU>Brown AFT</AU>
<TI>Therapeutic controversies in the management of acute anaphylaxis</TI>
<SO>Journal of Accident &amp; Emergency Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2001" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Brown 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brown AF, McKinnon D, Chu K</AU>
<TI>Emergency department anaphylaxis: a review of 142 patients in a single year</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>861-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004a" MODIFIED="2008-06-27 08:37:13 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Brown SG, Blackman KE, Stenlake V, Heddle RJ</AU>
<TI>Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation</TI>
<SO>Emergency Medicine Journal</SO>
<YR>2004</YR>
<VL>21</VL>
<PG>149-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004b" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Brown 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Brown SG</AU>
<TI>Clinical features and grading of anaphylaxis</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>114</VL>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2005" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Brown 2005" TYPE="JOURNAL_ARTICLE">
<AU>Brown SGA</AU>
<TI>Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis</TI>
<SO>Current Opinion in Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2006" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Brown 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brown SG</AU>
<TI>Anaphylaxis: clinical concepts and research priorities</TI>
<SO>Emergency Medicine Australasia</SO>
<YR>2006</YR>
<VL>18</VL>
<PG>155-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chamberlain-1999" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Chamberlain 1999" TYPE="JOURNAL_ARTICLE">
<AU>Chamberlain D</AU>
<TI>Emergency medical treatment of anaphylactic reactions. Project team of the resuscitation council (UK)</TI>
<SO>Journal of Accident &amp; Emergency Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2006" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Clark 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clark S, Gaeta TJ, Kamarthi GS, Camargo CA</AU>
<TI>ICD-9-CM coding of emergency department visits for food and insect sting allergy</TI>
<SO>Annals of Epidemiology</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>696-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dec-Helsinki--1996" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Dec Helsinki  1996" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Declaration of Helsinki</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1448-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta- analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fischer-1995" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Fischer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Fischer M</AU>
<TI>Fortnightly review: treatment of acute anaphylaxis</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>731-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-1978" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Fisher 1978" TYPE="JOURNAL_ARTICLE">
<AU>Fisher MM</AU>
<TI>Acute life-threatening reactions to contrast media</TI>
<SO>Aust Radiol</SO>
<YR>1978</YR>
<VL>22</VL>
<PG>365-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberger-2007" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Greenberger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Greenberger PA, Rotskoff BD, Lifschultz B</AU>
<TI>Fatal anaphylaxis: postmortem findings and associated comorbid diseases</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2007</YR>
<VL>98</VL>
<PG>252-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebling-2004" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Hebling 2004" TYPE="JOURNAL_ARTICLE">
<AU>Helbling A, Hurni T, Mueller UR, Pichler WJ</AU>
<TI>Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>2004</YR>
<VL>34</VL>
<PG>285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heilborn-1986" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Heilborn 1986" TYPE="JOURNAL_ARTICLE">
<AU>Heilborn H, Hjemdahl P, Daleskog M, Adamsson U</AU>
<TI>Comparison of subcutaneous injection and high-dose inhalation of epinephrine ? implications for self-treatment to prevent anaphylaxis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1986</YR>
<VL>76</VL>
<PG>1174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-11-30 12:37:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2009" TYPE="OTHER">
<TI>Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.0.2 [updated September 2009] 
</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansson-2001" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Johansson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al</AU>
<TI>A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force</TI>
<SO>Allergy</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>813-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansson-2004" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Johansson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al</AU>
<TI>Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<PG>832-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnston-2003" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Johnston 2003" TYPE="JOURNAL_ARTICLE">
<AU>Johnston SL, Unsworth J, Gompels M</AU>
<TI>Adrenaline given outside the context of life threatening allergic reactions</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>589-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemp-2002" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Kemp 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kemp SF, Lockey RF</AU>
<TI>Anaphylaxis: a review of causes and mechanisms</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2002</YR>
<VL>110</VL>
<PG>341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-1995" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Klein 1995" TYPE="JOURNAL_ARTICLE">
<AU>Klein JS, Yocum MW</AU>
<TI>Underreporting of anaphylaxis in a community emergency room</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>1995</YR>
<VL>95</VL>
<PG>637-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kounis-2006" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Kounis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kounis NG</AU>
<TI>Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm?</TI>
<SO>International Journal of Cardiology</SO>
<YR>2006</YR>
<VL>110</VL>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2003" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Lieberman 2003" TYPE="BOOK_SECTION">
<AU>Lieberman PL</AU>
<TI>Anaphylaxis and anaphylactoid reactions</TI>
<SO>Middleton's Allergy: Principles and Practice, 6th edition</SO>
<YR>2003</YR>
<PB>Mosby</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2006" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Lieberman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman P, Camargo C, Bohlke K, Jick H, Miller R, Sheikh A, et al</AU>
<TI>Epidemiology of anaphylaxis: findings of the ACAAI Epidemiology of Anaphylaxis Working Group</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2006</YR>
<VL>97</VL>
<PG>596-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-2000" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Lin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al</AU>
<TI>Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>106</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marone-2004" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Marone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marone G, Bova M, Detoraki A, Onorati AM, Rossi FW, Spadaro G</AU>
<TI>The human heart as a shock organ in anaphylaxis</TI>
<SO>Novartis Foundation Symposium</SO>
<YR>2004</YR>
<VL>257</VL>
<PG>133-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLean_x002d_Tooke-2003" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="McLean-Tooke 2003" TYPE="JOURNAL_ARTICLE">
<AU>McLean-Tooke AP, Bethune CA, Fay AC, Spickett GP</AU>
<TI>Adrenaline in the treatment of anaphylaxis: what is the evidence?</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>1332-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mink-2004" MODIFIED="2008-06-27 08:39:42 +0100" MODIFIED_BY="[Empty name]" NAME="Mink 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mink SN, Simons FER, Simons KJ, Becker AB, Duke K</AU>
<TI>Constant infusion of epinephrine, but not bolus treatment, improves haemodynamic recovery in anaphylactic shock in dogs</TI>
<SO>Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>34</VL>
<PG>1776-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montanaro-2002" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Montanaro 2002" TYPE="JOURNAL_ARTICLE">
<AU>Montanaro A, Bardana EJ Jr</AU>
<TI>The mechanisms, causes and treatment of anaphylaxis</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>2002</YR>
<VL>1</VL>
<PG>2-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muller-2007" MODIFIED="2008-06-27 08:50:22 +0100" MODIFIED_BY="[Empty name]" NAME="Muller 2007" TYPE="JOURNAL_ARTICLE">
<AU>Muller U</AU>
<TI>Cardiovascular disease and anaphylaxis</TI>
<SO>Current Opinion in Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>337-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neugut-2001" MODIFIED="2008-06-27 08:43:12 +0100" MODIFIED_BY="[Empty name]" NAME="Neugut 2001" TYPE="JOURNAL_ARTICLE">
<AU>Neugut AI, Ghatak AT, Miller RL</AU>
<TI>Anaphylaxis in the United States: an investigation into its epidemiology</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2001</YR>
<VL>161</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peng-2004" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Peng 2004" TYPE="JOURNAL_ARTICLE">
<AU>Peng MM, Jick H</AU>
<TI>A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<PG>317-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pumphrey-2000" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Pumphrey 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pumphrey RS</AU>
<TI>Lessons for management of anaphylaxis from a study of fatal reactions</TI>
<SO>Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>1144-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pumphrey-2007" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Pumphrey 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pumphrey RSH, Gowland MH</AU>
<TI>Further fatal allergic reactions to food in the United Kingdom, 1999-2006</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<PG>1018-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.0" MODIFIED="2008-06-20 10:38:45 +0100" MODIFIED_BY="Jane Cracknell" NAME="RevMan 5.0" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan). Version 5.0</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sampson-1992" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Sampson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sampson HA, Mendelson L, Rosen JP</AU>
<TI>Fatal and near-fatal anaphylactic reactions to food in children and adolescents</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>380-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sampson-2005" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Sampson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sampson HA, Munoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al</AU>
<TI>Symposium on the definition and management of anaphylaxis: summary report</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>584-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sampson-2006" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Sampson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al</AU>
<TI>Second symposium on the definition and management of anaphylaxis: summary report. Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2006</YR>
<VL>117</VL>
<PG>391-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheikh-2001" MODIFIED="2008-06-27 08:41:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sheikh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sheikh A, Alves B</AU>
<TI>Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data</TI>
<SO>Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>31</VL>
<PG>1571-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sicherer-2005" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Sicherer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sicherer SH, Simons FER</AU>
<TI>Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>575-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-1998" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Simons 1998" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER</AU>
<TI>Epinephrine absorption in children with a history of anaphylaxis</TI>
<SO>Journal of Clinical Immunology</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2000" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Simons 2000" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER, Gu X, Johnston L, Simons KJ</AU>
<TI>Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis?</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>106</VL>
<PG>1040-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2001" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Simons 2001" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER, Gu X, Simons KJ</AU>
<TI>Epinephrine absorption in adults: intramuscular versus subcutaneous injection</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>871-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2002a" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Simons 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER, Peterson S, Black CD</AU>
<TI>Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2002</YR>
<VL>110</VL>
<PG>647-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2002b" MODIFIED="2008-06-27 08:42:51 +0100" MODIFIED_BY="[Empty name]" NAME="Simons 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER, Chad ZH, Gold M</AU>
<TI>Real-time reporting of anaphylaxis in infants, children and adolescents by physicians involved in the Canadian Pediatric Surveillance Program</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2002</YR>
<VL>109 Suppl</VL>
<PG>181</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2004" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Simons 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER</AU>
<TI>First-aid treatment of anaphylaxis to food: Focus on epinephrine</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<PG>837-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2006" MODIFIED="2008-08-04 13:24:31 +0100" MODIFIED_BY="[Empty name]" NAME="Simons 2006" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER</AU>
<TI>Anaphylaxis, killer allergy: Long-term management in the community</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2006</YR>
<VL>117</VL>
<PG>367-77</PG>
<IDENTIFIERS MODIFIED="2008-08-04 13:24:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2007a" MODIFIED="2008-08-04 13:49:40 +0100" MODIFIED_BY="[Empty name]" NAME="Simons 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER, Frew AJ, Ansotegui IJ, Bochner BS, Finkelman F, Golden DBK, et al</AU>
<TI>Risk assessment in anaphylaxis: current and future approaches</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>120 Suppl</VL>
<PG>2-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2007b" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Simons 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Simons FE, Sheikh A</AU>
<TI>Evidence-based management of anaphylaxis</TI>
<SO>Allergy</SO>
<YR>2007</YR>
<VL>62</VL>
<PG>827-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2008" MODIFIED="2008-08-04 13:39:44 +0100" MODIFIED_BY="[Empty name]" NAME="Simons 2008" TYPE="JOURNAL_ARTICLE">
<AU>Simons FER</AU>
<TI>Emergency treatment of anaphylaxis: Revised UK guidelines are a concise evidence based resource</TI>
<SO>British Medical Journal</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>1141-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soar-2008" MODIFIED="2008-08-04 13:27:46 +0100" MODIFIED_BY="[Empty name]" NAME="Soar 2008" TYPE="JOURNAL_ARTICLE">
<AU>Soar J, Pumphrey R, Cant A, et al, for the Working Group of the Resuscitation Council (UK)</AU>
<TI>Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers</TI>
<SO>Resuscitation</SO>
<YR>2008</YR>
<VL>77</VL>
<PG>157-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yocum-1999" MODIFIED="2008-06-04 13:17:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Yocum 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD</AU>
<TI>Epidemiology of anaphylaxis in Olmsted County: A population-based study</TI>
<SO>The Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>452-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-05-26 11:16:15 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-05-26 11:16:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-26 16:37:58 +0100" MODIFIED_BY="Jane Cracknell"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<FIGURE FILENAME="CARG 118 fig.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Search flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVwAAAHQCAIAAABiBkXYAAAeCUlEQVR42u3dPW7cOB+AcZcpcxSX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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2008-06-04 12:44:20 +0100" MODIFIED_BY="Karen Hovhannisyan">Search strategy for CENTRAL, <I>The Cochrane Library</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<P>#1 MeSH descriptor Anaphylaxis explode all trees<BR/>#2 anaphylact* near (react* or shock* or syndrom*)<BR/>#3 acute near (allergic react*)<BR/>#4 anaphylaxis<BR/>#5 (#1 OR #2 OR #3 OR #4)<BR/>#6 MeSH descriptor Sympathomimetics explode all trees<BR/>#7 MeSH descriptor Catecholamines explode all trees<BR/>#8 MeSH descriptor Epinephrine explode all trees<BR/>#9 MeSH descriptor Norepinephrine explode all trees<BR/>#10 sympathomimetic* or Catecholamin* or Adrenalin* or Epinephrin* or Noradrenalin* or EpiPen or Anapen*<BR/>#11 (#6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 (#5 AND #11)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for MEDLINE (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<P>1. exp Anaphylaxis/ or (anaphyla* adj3 (react* or shock* or syndrome* or systemic or idiopathic)).mp. or (acute adj3 allergic react*).mp. <BR/>2. exp sympathomimetics/ or Catecholamines/ or Adrenaline/ or Epinephrine/ or Noradrenaline/ or (epipen or anapen or catecholamine* or epinephrin* or noradrenalin* or adrenalin*).mp. <BR/>3. 1 and 2 <BR/>4. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (animals not (humans and animals)).sh. <BR/>5. 3 and 4 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell" NO="3">
<TITLE MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for EMBASE (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<P>1. exp anaphylaxis/ or exp anaphylactic shock/ or (anaphyla* adj3 (react* or shock* or syndrome* or systemic or idiopathic)).mp. or (acute adj3 allergic react*).mp. <BR/>2. exp adrenergic receptor stimulating agent/ or exp catecholamine/ or exp catecholamine/ or noradrenalin/ or (epipen or anapen or catecholamine* or epinephrin* or noradrenalin* or adrenalin*).mp. <BR/>3. 1 and 2 <BR/>4. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* or factorial* or placebo* or volunteer* or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*))).ti,ab.) not (animals not (humans and animals)).sh. <BR/>5. 3 and 4 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell" NO="4">
<TITLE MODIFIED="2008-06-04 13:01:48 +0100" MODIFIED_BY="Karen Hovhannisyan">Search strategy for CINAHL (EBSCO host)</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<P>S1   (MM "Anaphylaxis")<BR/>S2   TX anaphylax* or anaphilact*<BR/>S3   S1 or S2<BR/>S4   (MH "Sympathomimetics+")<BR/>S5   (MH "Catecholamines+")<BR/>S6   (MH "Epinephrine")<BR/>S7   TX sympathomimetic* or Catecholamin* or Adrenalin* or Epinephrin* or Noradrenalin* or EpiPen or Anapen*<BR/>S8   S4 or S5 or S6 or S7<BR/>S9   S3 and S8</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell" NO="5">
<TITLE MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for BIOSIS Previews (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-18 10:42:45 +0100" MODIFIED_BY="Jane Cracknell">
<P>1 (anaphylact* or anaphylax* or (acute adj3 allergic)).mp. <BR/>2 (epipen or anapen or catecholamine* or epinephrin* or noradrenalin* or adrenalin*).mp. <BR/>3 1 and 2 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2008-06-04 13:16:07 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="6">
<TITLE MODIFIED="2008-06-04 13:13:04 +0100" MODIFIED_BY="Karen Hovhannisyan">Search strategy for ISI Web of Science</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-04 13:16:07 +0100" MODIFIED_BY="Karen Hovhannisyan">
<P>(TS=anaphylax* OR TS=anaphylact*) AND (TS=Sympathomimetic* OR TS=Catecholamin* OR TS=Adrenalin* OR TS=Epinephrin* OR TS=Noradrenalin* OR TS=EpiPen OR TS=Anapen)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell" NO="7">
<TITLE MODIFIED="2008-06-04 13:09:48 +0100" MODIFIED_BY="Karen Hovhannisyan">Search strategy for LILACS (BIREME)</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-24 12:23:21 +0000" MODIFIED_BY="Jane Cracknell">
<P>("epipen" or "anapen" or "catecholamine" or "epinephrine" or "noradrenaline" or "adrenaline") and ("ANAPHYLAXIA" or "ANAPHYLAXIS" or "ANAPHYLAXIS/" or "ANAPHYLACTIC REACTION" or "ANAPHYLACTIC REACTION/" or "anaphylax$" or "anaphylact$") 
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2008-06-04 13:13:08 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="8">
<TITLE MODIFIED="2008-05-26 16:37:39 +0100" MODIFIED_BY="Jane Cracknell">List of experts and pharmaceutical companies contacted</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-26 16:37:54 +0100" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="1" ROWS="28">
<TR>
<TH>
<P>Contact names</P>
</TH>
</TR>
<TR>
<TD>
<P>Prof. H.A. Sampson</P>
</TD>
</TR>
<TR>
<TD>
<P>Prof. A.F. Brown</P>
</TD>
</TR>
<TR>
<TD>
<P>Prof. J.M. Negro-Alvarez</P>
</TD>
</TR>
<TR>
<TD>
<P>Prof. A.D. Moneret - Vautrin</P>
</TD>
</TR>
<TR>
<TD>
<P>Prof. U Muller</P>
</TD>
</TR>
<TR>
<TD>
<P>Prof. M Fisher</P>
</TD>
</TR>
<TR>
<TD>
<P>Prof. J Ring</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. L.P. Lieberman</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. P.W. Ewan</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. R.S. Pumphrey</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. A. Helbling</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. R Lin</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. S Clark</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. D Golden</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. R Lockey</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. A Bock</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. S Kemp</P>
</TD>
</TR>
<TR>
<TD>
<P>Dr. C Camargo</P>
</TD>
</TR>
<TR>
<TD>
<P>ALK-Abelló (UK) Ltd</P>
</TD>
</TR>
<TR>
<TD>
<P>Abbott Laboratories Ltd</P>
</TD>
</TR>
<TR>
<TD>
<P>UCB Pharma Ltd</P>
</TD>
</TR>
<TR>
<TD>
<P>Meridian Medical Technology Inc</P>
</TD>
</TR>
<TR>
<TD>
<P>Cell Therapeutics (UK) Ltd</P>
</TD>
</TR>
<TR>
<TD>
<P>CSL Biotherapies</P>
</TD>
</TR>
<TR>
<TD>
<P>Lincoln Medical Ltd</P>
</TD>
</TR>
<TR>
<TD>
<P>Dey Laboratories</P>
</TD>
</TR>
<TR>
<TD>
<P>International Medication Systems (UK) Ltd</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>